Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Fingerprint

Dive into the research topics of 'Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy'. Together they form a unique fingerprint.

Medicine & Life Sciences